Gilead’s Remdesivir Wins FDA’s First COVID-19 Drug Approval

Eight months after it was first tested in human patients at the center of the world’s first COVID-19 outbreak, Gilead Sciences’ antiviral remdesivir won the FDA’s first approval of a drug against the virus—but for a smaller population than allowed under its previous emergency use authorization from the agency.

Full Story